BSX - Boston Scientific Corporation
| Previous Close | 36.72 |
| Open | 36.74 |
| Bid | 35.51 x 4000 |
| Ask | 37.99 x 4000 |
| Day's Range | 36.47 - 36.87 |
| 52 Week Range | 25.04 - 39.44 |
| Volume | 5,535,844 |
| Avg. Volume | 7,627,455 |
| Market Cap | 50.675B |
| Beta (3Y Monthly) | 0.93 |
| PE Ratio (TTM) | 75.82 |
| EPS (TTM) | 0.48 |
| Earnings Date | Feb 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.22 |
- CNBC Videos•20 days ago
Buy UnitedHealth ahead of earnings? Does Caterpillar look...
The "Halftime Report" traders take viewer questions on Caterpillar, Gilead, Boston Scientific, Caterpillar, and Twitter.
- Investor's Business Daily•2 days ago
Why An IBD 50 Stock And Its Close Rival Are Nearing Breakouts
Edwards Lifesciences and Boston Scientific stocks hit one-month highs Tuesday after the duo settled a patent battle related to transcatheter aortic heart-valve replacements.
- TheStreet.com•2 days ago
Edwards Lifesciences' Stock Jumps on Patent Dispute Settlement
surged nearly 8% on Tuesday after the company agreed to pay rival Boston Scientific Corp. $180 million to settle long-standing patent disputes over heart valve replacement devices. At midday, Edwards Lifesciences' stock rose 8.4% to $162.09 at the close of trading on the New York Stock Exchange.
- American City Business Journals•2 days ago
Boston Scientific settles global heart valve legal battles for $180M
The tools Boston Scientific and Edwards Lifesciences have battled over are used during a relatively new, multibillion-dollar cardiac treatment called transcatheter aortic valve replacement (TAVR).
- Market Realist•2 days ago
Boston Scientific and Edward Lifesciences Settle Patent Dispute
Boston Scientific and Edward Lifesciences Settle Patent DisputeThe stock performance of BSXToday, Boston Scientific (BSX) is trading at $36.76, which is ~4.11% growth from yesterday’s closing price of $35.31. Boston Scientific stock closed at
- Reuters•2 days ago
Edward Lifesciences pays Boston Scientific $180 mln to end patent row
Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers. Boston Scientific and Edwards Lifesciences have been embroiled in a number of legal cases for several years involving heart valve replacement systems, including transcatheter aortic valves, in the United States and Europe. All pending cases or appeals in courts and patent offices will be dismissed, the companies said in a joint statement on Tuesday.
- Markit•2 days ago
See what the IHS Markit Score report has to say about Boston Scientific Corp.
# Boston Scientific Corp ### NYSE:BSX View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for BSX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $11.58 billion over the last one-month into ETFs that hold BSX are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. BSX credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Reuters•2 days ago
Edward Lifesciences settles patent disputes with Boston Scientific
Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement related to all outstanding patent disputes between the companies, the medical device makers said in ...
- PR Newswire•2 days ago
Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
All Patent Litigation Between the Companies to be Dismissed MARLBOROUGH, Mass. and IRVINE, Calif. , Jan. 15, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and Edwards Lifesciences Corporation ...
- Zacks•3 days ago
The Zacks Analyst Blog Highlights: Boston Scientific, Southern, BNY, Schlumberger and Southwest
The Zacks Analyst Blog Highlights: Boston Scientific, Southern, BNY, Schlumberger and Southwest
- Investor's Business Daily•6 days ago
Why This Group Is 'An Attractive Destination For Investors' In 2019
Medical technology stalwarts Abbott Laboratories, Johnson & Johnson and Medtronic will likely face exchange-rate headwinds in 2019, an analyst said Friday. But he stayed bullish on medtech.
- Zacks•6 days ago
Top Analyst Reports for Boston Scientific, Southern Company & BNY Mellon
Top Analyst Reports for Boston Scientific, Southern Company & BNY Mellon
- Markit•8 days ago
See what the IHS Markit Score report has to say about Boston Scientific Corp.
# Boston Scientific Corp ### NYSE:BSX View full report here! ## Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for BSX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding BSX is favorable, with net inflows of $18.66 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. BSX credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•8 days ago
Boston Scientific Gains on Impressive Preliminary Q4 Results
Boston Scientific's (BSX) solid top line is expected to be backed by growth across all segments and geographical regions in Q4.
- MarketWatch•9 days ago
Boston Scientific reports preliminary sales in line with expectations
Boston Scientific Corp. reported Tuesday it preliminary fourth-quarter sales of $2.56 billion, up 6.3% from a year ago and in line with the FactSet consensus. The medical technology company's stock was still inactive in premarket trade. Among its business units, MedSurg revenue rose 7.5% to $800 million, Rhythm and Neuro sales grew 5.3% to $790 million and Cardiovascular sales increased 6.4% to $970 million. The company is expected to report full fourth-quarter results in early February. The stock has lost 7.7% over the past three months, while the SPDR Health Care Select Sector ETF has declined 8.5% and the S&P 500 has shed 11.6%.
- PR Newswire•9 days ago
Boston Scientific Announces Preliminary Unaudited Sales for the Fourth Quarter and Full Year 2018
MARLBOROUGH, Mass. , Jan. 8, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.56 billion during ...
- Investopedia•10 days ago
Top 5 Health Care Stocks of 2018 by Performance
The healthcare sector performed well in 2018, driven by positive growth in sub-segments such as medical devices, health insurance, hospitals, nursing homes, and pharmaceuticals, which offset losses in biomedical and genetics, home healthcare, medical, and dental supplies. Moving ahead into 2019, as the decade-long expansion faces a period of heightened volatility and risk, the health care sector should benefit from a shift towards more defensive sectors. In a recent sector roundup from Charles Schwab, the firm rated health care at "outperform," citing the group’s strong balance sheets, attractive dividend yields, and improved cost structure.
- InvestorPlace•10 days ago
3 Stock Charts for Monday: Gap, CenterPoint Energy and Boston Scientific
Any doubters who got out of the stock market on Thursday -- or worse, shorted stocks in the midst of that weakness -- were blindsided on Friday. The S&P 500 jumped 3.43% on the last day of last week, bolstering the argument that the market is ready to recover. Apple (NASDAQ:AAPL) set the tone and the pace, bouncing back from Thursday's plunge with a 4.3% rebound. As it turns out, investors aren't quite so sure the company's in dire straits after all. Netflix (NASDAQ:NFLX) had the bigger and better day, however, advancing 9.7% after Goldman Sachs said the recent pullback was a buying opportunity. Losers were few and far between, though among the most noteworthy was Cue Biopharma (NASDAQ:CUE). Shares of the biotech stock tumbled 6.3%, though traders are still looking for a specific reason for the selling. So far, it can only be chalked up to volatility. InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the big day on Friday certainly positions most stocks for more bullishness this week, the weekend and the sheer scope of the recent gains still poses the risk of profit-taking. Fortunately, stocks charts of Gap (NYSE:GPS), Boston Scientific (NYSE:BSX) and CenterPoint Energy (NYSE:CNP) look well positioned to move into trends regardless of what the broad market does, after several days of jockeying. ### Boston Scientific (BSX) In the middle of 2018, Boston Scientific looked unstoppable. Shares were not only in rally mode, they had broken past a major technical ceiling that had defined an uptrend that goes back to 2015. * 10 Oversold Stocks Due for a Bounce In retrospect though, that big run-up looks like it was only a setup for an even bigger corrective move. That's now well underway, but hardly complete yet. Click to Enlarge • BSX shares managed to pop back above the 200-day moving average line, plotted in white as of Friday, but one day doesn't bring the stock all the way back from that cliff's edge. • The most plausible downside target is a pullback to the same support line that's tagged all the major lowers going back to 2015. That level is currently at $29.00, but rising fast. • Any major bottom should also coincide with a stochastic indicator falling all the way below 20, and an RSI indicator that gets near there. That's the condition we saw take shape with past lows that led to recovery rallies. ### CenterPoint Energy (CNP) The 1.9% advance utility name CenterPoint Energy logged on Friday actually trailed the broad market's gain. But that gain is part of a much bigger breakout thrust effort that the broad market can't boast right now. It's unlikely we'll see a straight shot past the make-or-break technical ceiling ahead, but the slow bullish momentum is still well-established momentum. Click to Enlarge • The pivotal line is right around $29, plotted in blue on both stock charts. CenterPoint Energy shares have actually been above that mark since 2017, but not in a "normal" scenario. • It's evident on the daily chart, but more evident on the weekly chart that the $27/$29 span has been a trading range. The consolidation between those two lines has set the stage for a prolonged advance of $29 can be cleared. • Underscoring the bullish argument is the fact that CenterPoint is one of the few stocks with all key moving average lines sloped upward rather than downward. It's an indication of bullishness in multiple timeframes. ### Gap (GPS) Just because a stock loses ground on a day that the overall market moves higher doesn't inherently make that name un-ownable. On the other hand, any stock that isn't swept higher in a bullish charge likes Friday's can and should raise eyebrows. Gap is such a name, falling 1.6% on Friday and extending a well-established downtrend. Click to Enlarge • Friday's loss wasn't just an erroneous slide. It was a high-volume selloff that dragged Gap shares back under the falling 20-day moving average, which is one of several moving average lines that have steered the stock lower for months. • Notice that all the key moving average lines made bearish crosses between July and September. • Zooming out to a weekly chart we can see Friday's weakness is part of a well-defined downtrend that extends back to early last year. Since then, their divergences have widened. As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Downtrodden Stocks to Fish From the Bottom * 8 Cheap Value Stocks That Just Got More Enticing * 5 Apple Suppliers Hurt by the Guidance Cut Compare Brokers The post 3 Stock Charts for Monday: Gap, CenterPoint Energy and Boston Scientific appeared first on InvestorPlace.
- PR Newswire•13 days ago
Boston Scientific Announces Conference Call Discussing Fourth Quarter 2018 Financial Results And Investor Update At NANS 2019
MARLBOROUGH, Mass. , Jan. 4, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter ...
- Market Realist•13 days ago
GE’s Healthcare Unit Spin-Off to Enhance Shareholder Wealth
Will Restructuring Initiatives Put GE Back on Growth Trajectory? As part of its June 2018 major restructuring plan, General Electric (GE) intends to spin off the Healthcare segment and turn it into a standalone entity. The move is believed to be another step by newly appointed CEO Larry Culp to optimize the company’s business and strengthen its liquidity position.
- Barrons.com•17 days ago
New Study Raises Concerns About Overuse of Stents
Stent manufacturers such as Abbott Laboratories and Medtronic still expect demand for stents to remain steady.
- Zacks•17 days ago
Boston Scientific (BSX) to Buy Residual Shares of Millipede
Boston Scientific's (BSX) buyout of the leftover stake in Millipede will integrate the latter's IRIS Transcatheter Annuloplasty Ring System in the Structural Heart portfolio of the former.
- MarketWatch•18 days ago
Boston Scientific’s latest deal is a good fit, analysts say
Boston Scientific’s latest deal, a takeover of privately held Millipede, will help the company build out its franchise of heart-valve repair and replacement treatments, Needham analysts said Thursday.
- GOBankingRates•18 days ago
14 of the Best Performing Stocks in 2018
See which stocks made major moves in 2018.
- Investor's Business Daily•20 days ago
Will A New Approval Help This Medical Stock Approach A Breakout?
Edwards Lifesciences gained approval for a new transcatheter heart-valve replacement, or TAVR, system Friday — helping its stock to stay within a consolidation.
